Neoton (Phosphocreatine Sodium)

Phosphocreatine sodium, the active ingredient in Neoton, is an energy metabolism agent presented as an intravenous solution for intravenous use. It supports cardiac energy metabolism and is used in cardiovascular care to help maintain myocardial ATP levels. GNH USA supplies Neoton as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Neoton is employed in cardiovascular medicine to support myocardial energy metabolism and improve cardiac function. - Acute myocardial infarction: helps restore ATP levels in ischemic heart muscle. - Chronic heart failure: assists in maintaining cardiac contractility during decompensation. - Cardiac surgery: provides myocardial protection during cardiopulmonary bypass and reperfusion.

Phosphocreatine sodium may be associated with a range of adverse reactions.

Common Side Effects: - Injection site pain: mild discomfort at the infusion site. - Hypotension: transient drop in blood pressure during administration. - Nausea: occasional feeling of queasiness. - Headache: mild to moderate headache. - Flushing: transient skin reddening. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Arrhythmia: abnormal heart rhythm, especially with high doses. - Myocardial ischemia: worsening of heart muscle oxygen deficiency. - Anaphylactic reaction: severe allergic response requiring immediate treatment. - Hyperkalemia: elevated blood potassium levels. - Severe hypotension: marked blood pressure fall needing intervention.

When using Neoton, clinicians should consider several safety measures. - Cardiac monitoring: observe rhythm and hemodynamics during infusion. - Electrolyte balance: check serum potassium and calcium before and after dosing. - Renal function: assess kidney function as impaired clearance may affect drug levels. - Concomitant inotropes: adjust doses of other cardiac stimulants to avoid excess activity. - Pregnancy and lactation: use only if benefits outweigh potential risks, as data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Phosphocreatine sodium can interact with other cardiovascular agents, requiring careful management.

Major Interactions (Avoid): - Concurrent high‑dose inotropes: may increase risk of arrhythmia. - Potassium‑sparing diuretics: can exacerbate hyperkalemia.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt desired inotropic effect. - Calcium channel blockers: potential additive hypotensive effect. - ACE inhibitors or ARBs: monitor blood pressure and renal function. - Nitrates: watch for excessive vasodilation. - Anticoagulants: observe for bleeding if hemodynamic changes occur.